Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A synthetic heptapeptide analog of tuftsin developed by the Institute of Molecular Genetics in Russia. Approved in Russia as an anxiolytic and nootropic. Widely used for anxiety reduction and cognitive enhancement without sedation.
A nonapeptide (9 amino acids) first isolated from rabbit cerebral venous blood in 1977. Originally studied for sleep-induction properties, it is now being investigated for opioid withdrawal and chronic insomnia.
Modulates GABA-A receptor activity and increases BDNF expression. Stabilizes enkephalins (endogenous opioid peptides) by inhibiting their enzymatic breakdown, prolonging their anxiolytic effects. Also modulates serotonin, dopamine, and norepinephrine systems.
Modulates the sleep-wake cycle through interactions with opioid, serotonin, and other neurotransmitter systems. Reduces the activity of stress-response systems. Mechanism is not fully characterized, but effects appear to be on circadian regulation and stress adaptation.
- Anxiety and stress reduction
- Cognitive enhancement and focus
- Depression support
- Immune system modulation
- Memory improvement
- Sleep quality improvement
- Opioid withdrawal support
- Stress and cortisol reduction
- Chronic insomnia
- Narcolepsy (investigational)
- Limited Western clinical trial data
- Nasal spray may cause mild irritation
- Potential fatigue at higher doses
- Long-term safety profile not established in Western populations
- Interactions with other anxiolytics not well characterized
- Limited human clinical data
- Mechanism not fully understood
- Potential interactions with opioid medications
- Inconsistent results across studies
- Long-term effects unknown
Not FDA-approved and not currently on any FDA compounding list. Available as a research chemical. Approved in Russia as an anxiolytic drug. Not affected by the April 2026 Category 2 removal action.
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 24, 2026 for opioid withdrawal, chronic insomnia, and narcolepsy indications. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
PCAC: July 24, 2026
- Delta sleep-inducing peptide (DSIP): a review
1984 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.